Floatz logo

TACROLIMUS

Mental Disorder

Stanford UniversitySmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Mental Disorder cohort.

Asset / SponsorPhaseRating
Liraglutide
Anders Fink-Jensen, MD, DMSci
Phase 4BB
Opc-34712
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
University Hospital, Bordeaux
Phase 3B
Cipralex
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2B
CITALOPRAM
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2CCC
Sertraline
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2CCC

Same molecule, other indications

TACROLIMUS is also rated in:

disease related to transplantationDormant
BBB
Indicative ·
79 / 100
View asset →
disease related to solid organ transplantationDormant
BBB
Indicative ·
76 / 100
View asset →
beta-thalassemia majorDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →